Nifedipine Adverse Effects and Clinical Recommendations

Common Adverse Effects

Peripheral edema occurs in roughly one‑fifth to one‑third of individuals receiving nifedipine, with incidence rising with higher daily doses (≈18 % at low dose, ≈22 % at moderate dose, ≈29 % at high dose) compared with about 10 % on placebo【1】【2】【3】.
Hypotension is a frequent adverse event, particularly with immediate‑release formulations, and may be severe enough to necessitate discontinuation of therapy【1】【2】【3】.
Headache is commonly reported and is usually of moderate intensity【1】【2】【3】.
Flushing is a frequent, typically mild complaint【1】【2】【3】.
Dizziness is reported more often with nifedipine than with other calcium‑channel blockers such as nicardipine【1】【2】【3】.
Nausea and constipation are also common gastrointestinal side effects【1】【2】【3】.

Reflex tachycardia can develop, especially with dihydropyridine‑type agents like nifedipine【4】.
Extended‑release nifedipine formulations are generally better tolerated than immediate‑release preparations, showing fewer cardiovascular adverse events【1】【2】【3】.

The American College of Cardiology/American Heart Association (ACC/AHA) guidelines advise that rapid‑release, short‑acting nifedipine should be avoided unless the patient is concurrently receiving β‑blockade, because of an increased risk of myocardial infarction and other cardiovascular events【1】【2】【3】【5】.
The European Society of Cardiology (ESC) recommends that immediate‑release nifedipine be avoided altogether, particularly in older adults (≥ 75 years), due to heightened risk of hypotension and heart‑failure exacerbation【4】.

Worsening heart failure occurs in less than 3 % of patients, especially those with pre‑existing left‑ventricular dysfunction【1】【3】【6】.
Nifedipine should be avoided in individuals with pulmonary edema or severe left‑ventricular dysfunction because of the potential for decompensation【1】【2】【3】.